{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:48:55Z","timestamp":1791154135228,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.antiviral.2011.09.010","type":"journal-article","created":{"date-parts":[[2011,10,9]],"date-time":"2011-10-09T11:34:25Z","timestamp":1318160065000},"page":"484-487","source":"Crossref","is-referenced-by-count":31,"title":["The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment"],"prefix":"10.1016","volume":"92","author":[{"given":"W. Jeffrey","family":"Fessel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Follansbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley T.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Weinheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2011.09.010_b0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0300-483X(02)00002-1","article-title":"Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates","volume":"172","author":"Boon","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.antiviral.2011.09.010_b0010","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.4049\/jimmunol.149.5.1779","article-title":"Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion","volume":"149","author":"Burkly","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2011.09.010_b0015","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.str.2010.09.017","article-title":"Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody","volume":"18","author":"Freeman","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2011.09.010_b0020","first-page":"39","article-title":"Antibodies for HIV treatment and prevention: window of opportunity?","volume":"317","author":"Huber","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2011.09.010_b0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/AAC.00942-08","article-title":"Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults","volume":"53","author":"Jacobson","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.09.010_b0030","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/652190","article-title":"Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody","volume":"201","author":"Jacobson","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.09.010_b0035","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1086\/380802","article-title":"Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1","volume":"189","author":"Kuritzkes","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.09.010_b0040","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/JVI.66.8.4784-4793.1992","article-title":"A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells","volume":"66","author":"Moore","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.09.010_b0045","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1089\/aid.1997.13.933","article-title":"A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties","volume":"13","author":"Reimann","year":"1997","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2011.09.010_b0050","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1128\/JVI.00453-10","article-title":"Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients","volume":"84","author":"Song","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.09.010_b0055","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1128\/JVI.02237-10","article-title":"Loss of asparagine-linked glycosylation sites in variable region five of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab","volume":"85","author":"Toma","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.09.010_b0060","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JVI.02006-06","article-title":"Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry","volume":"81","author":"Westby","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.09.010_b0065","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.00761-05","article-title":"Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20)","volume":"50","author":"Zhang","year":"2006","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211004487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211004487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T09:51:45Z","timestamp":1686390705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354211004487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0166354211004487"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2011.09.010","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}